

**PROPHYLAXIS VS ON-DEMAND
TREATMENT IN MODERATE
HAEMOPHILIA A PATIENTS
WITHOUT INHIBITORS IN EU5**

Brown S¹, Palau I¹, Rosli A², Seth EA²
¹Ipsos Mori UK Ltd., London, UK,
²Ipsos Sdn Bhd., KL, MY

OBJECTIVE

This study aims to compare the characteristics between patients receiving prophylaxis vs on-demand treatment among moderate haemophilia A patients without inhibitors in EU5: France (FR), Germany (DEU), Italy (IT), Spain (ES) and UK.

METHOD

Ipsos' Haemophilia Therapy Monitor is a multi-country, multi-centre online medical chart review study of patients with haemophilia A and B conducted between May and June 2020. De-identified data on patients in EU5 were collected from treating physicians recruited from an access panel; physicians were screened for duration of practice in their specialty and minimum caseload managed (5 Haemophilia A and 1 Haemophilia B moderate-severe patients in the last six months).

184 sampled physicians in EU5 provided data on 932 Haemophilia A patients. Descriptive statistics were used to analyse the results of 502 reported moderate Haemophilia A patients without inhibitors currently detected (FR: n=68, DEU: n=147; IT: n=112; ES: n=78; UK: n=97).


Statistical analysis of the data was performed using a t-test at 99% and 95% confidence levels.



RESULTS

- Of the 502 reported moderate Haemophilia A patients without inhibitors, 51.8% (n=260) receive prophylaxis treatment and 48.2% (n=242) receive on-demand treatment.
- Across the total EU5 reported patient sample, UK (61.9%), France (61.8%) and Germany (58.5%) have the highest proportion of moderate Haemophilia A patients receiving prophylaxis treatment; significantly higher than in Italy (40.2%) and Spain (34.6%).
See fig. 1
- Amongst 260 moderate Haemophilia A patients specifically managed with a prophylaxis approach, 60.8% (n=158) are receiving their first FVIII treatment since diagnosis; this is significantly lower than the 72.3% of 242 moderate Haemophilia A patients receiving on-demand treatment.

Figure 1: MODERATE HAEMOPHILIA A PATIENTS RECEIVING PROPHYLAXIS VS ON-DEMAND TREATMENT



RESULTS (CONT)

- The proportion of moderate Haemophilia A patients receiving prophylaxis with target joints is significantly higher than those receiving on-demand treatment (28.5% vs 14.9%, respectively). *See fig. 2*
- The proportion of moderate Haemophilia A patients receiving prophylaxis who are experiencing pain is significantly higher than those receiving on-demand treatment (79.2% vs 42.2%, respectively). *See fig. 3*
- Moderate Haemophilia A patients on prophylaxis treatment experienced an average of 3.1 bleeds within the last 12 months, whereas patients in the on-demand treatment group experienced a lower average number of bleeds within this time frame (1.8 bleeds).

Figure 2: % of moderate Haemophilia A patients receiving on-demand vs prophylaxis, who have target joints





Figure 3: % of moderate Haemophilia A patients receiving on-demand vs prophylaxis, who are experiencing pain



Source: Ipsos Haemophilia Monitor (May and June 2020, 184 doctors in EU5 reporting on 502 moderate Haemophilia A patients seen in consultation, data collected online. Participating doctors were primary treaters and saw a minimum number of patients per month) Data © Ipsos 2020, all rights reserved

CONCLUSIONS

Findings from this study highlights current variations between countries in the treatment approach used for moderate Haemophilia A patients without inhibitors; it will be interesting to see how this evolves in the future.

This study also underlines that moderate patients who are more complex, for example with target joints or experiencing pain, are more likely to be receiving prophylaxis treatment. Further study on treatment patterns is warranted.